Sydnexis to Present New Data from Phase 3 STAR Trial of SYD-101 at ARVO 2026 Annual Meeting
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Sydnexis to Present New Data from Phase 3 STAR Trial of SYD-101 at ARVO 2026 Annual Meeting
DEL MAR, Calif.--(BUSINESS WIRE)--Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced it will present new data related to a prespecified subgroup analysis in children with fast-progressing myopia from the Phase 3 STAR trial of SYD-101 at the Association for Research in Vision more... The post Sydnexis to Present New Data from Phase 3 …
Sydnexis to Present New Subgroup Data from Phase 3 STAR Trial of SYD-101 at ARVO 2026
Key Takeaways New Phase 3 STAR trial subgroup data will highlight SYD-101’s effects in children with fast-progressing myopia Presentation at ARVO 2026 underscores growing clinical interest in targeted interventions for pediatric myopia progression SYD-101’s formulation features—enhanced permeability, long-term stability, and near-neutral pH—aim to improve both efficacy and patient tolerability Sydnexis announced it will present new clinical da…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
